Cargando…

Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer

PURPOSE: Radiation therapy dose escalation using a simultaneous integrated boost (SIB) is predicted to improve local tumor control in esophageal cancer; however, any increase in acute hematologic toxicity (HT) could limit the predicted improvement in patient outcomes. Proton therapy has been shown t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Warren, Samantha, Hurt, Christopher N., Crosby, Thomas, Partridge, Mike, Hawkins, Maria A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science Inc 2017
Materias:	Physics Contribution
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612280/ https://www.ncbi.nlm.nih.gov/pubmed/29280467 http://dx.doi.org/10.1016/j.ijrobp.2017.07.025

Ejemplares similares

Radiobiological Determination of Dose Escalation and Normal Tissue Toxicity in Definitive Chemoradiation Therapy for Esophageal Cancer()
por: Warren, Samantha, et al.
Publicado: (2014)

An Analysis of Plan Robustness for Esophageal Tumors: Comparing Volumetric Modulated Arc Therapy Plans and Spot Scanning Proton Planning
por: Warren, Samantha, et al.
Publicado: (2016)

Impact of hematologic toxicities during concurrent chemoradiation for cervical cancer
por: Shi, Feiya, et al.
Publicado: (2022)

Achalasia Combined with Esophageal Cancer Treated by Concurrent Chemoradiation Therapy
por: Park, Jun Chul, et al.
Publicado: (2009)

Ultrasound-Mediated Gemcitabine Delivery Reduces the Normal-Tissue Toxicity of Chemoradiation Therapy in a Muscle-Invasive Bladder Cancer Model
por: Ruan, Jia-Ling, et al.
Publicado: (2021)

A Case of Recurrent Esophageal Cancer Treated with Concurrent Chemoradiation Therapy in Pregnancy
por: Yamada, Kaori, et al.
Publicado: (2018)

The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation
por: Carrington, Rhys, et al.
Publicado: (2015)

Long-term survival after concurrent chemoradiation therapy for esophageal cancer with tracheal invasion
por: Cho, Joon Hyun, et al.
Publicado: (2015)

Concurrent chemoradiation therapy tailored to the older adults with esophageal cancer: state of the art and the future
por: Song, Tao, et al.
Publicado: (2018)

Proton Therapy With Concurrent Chemotherapy for Thoracic Esophageal Cancer: Toxicity, Disease Control, and Survival Outcomes
por: Rutenberg, Michael S., et al.
Publicado: (2022)

The role of bone marrow and spleen irradiation in the development of acute hematologic toxicity during chemoradiation for esophageal cancer
por: Chin, Alexander L., et al.
Publicado: (2018)

Increasing Radiation Dose to the Thoracic Marrow Is Associated With Acute Hematologic Toxicities in Patients Receiving Chemoradiation for Esophageal Cancer
por: Fabian, Denise, et al.
Publicado: (2019)

Ultrahigh-Dose-Rate Proton Irradiation Elicits Reduced Toxicity in Zebrafish Embryos
por: Saade, Gaëlle, et al.
Publicado: (2022)

Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation
por: Kumar, T, et al.
Publicado: (2019)

The Utility of Proton Beam Therapy with Concurrent Chemotherapy for the Treatment of Esophageal Cancers
por: Lin, Steven H.
Publicado: (2011)

Comparison of platinum monotherapy with concurrent chemoradiation therapy versus platinum-based dual drug therapy with concurrent chemoradiation therapy for locally advanced cervical cancer: a systematic review and meta-analysis
por: Deng, Ting, et al.
Publicado: (2022)

Organ Preservation for Advanced Laryngeal Cancer: Experience with Concurrent Chemoradiation Therapy
por: Arain, Asif Ali, et al.
Publicado: (2020)

Improvement in Esophageal Distensibility in Response to Medical and Diet Therapy in Eosinophilic Esophagitis
por: Carlson, Dustin A, et al.
Publicado: (2017)

Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients
por: Zhao, Lina, et al.
Publicado: (2017)

Concurrent Chemoradiation for Vaginal Cancer
por: Miyamoto, David T., et al.
Publicado: (2013)

A pulmonary artery pseudoaneurysm caused by concurrent chemoradiation therapy for lung cancer
por: Kim, Jung Ho, et al.
Publicado: (2015)

Feasibility of Concurrent Chemoradiation in Patients treated for Esophageal Carcinoma: A Single Institutional Experience
por: Kannan, Ram Abhinav
Publicado: (2014)

Concurrent chemo-radiotherapy with proton therapy: reduced toxicity with comparable oncological outcomes vs photon chemo-radiotherapy
por: Baumann, Brian C., et al.
Publicado: (2020)

Quality-Adjusted Life Years and Disability-Adjusted Life Years Are Better With Concurrent Chemoradiation Therapy Than Induction Chemotherapy Followed by Chemoradiation Therapy in Nasopharyngeal Carcinoma
por: Nittala, Mary R, et al.
Publicado: (2021)

Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma
por: Haj Mohammad, Nadia, et al.
Publicado: (2014)

Variable uterine uptake of FDG in adenomyosis during concurrent chemoradiation therapy for cervical cancer
por: Yu, Jeong Il, et al.
Publicado: (2011)

MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma
por: Lin, Cheng-Han, et al.
Publicado: (2016)

Coverage and Cost-of-Care Links: Addressing Financial Toxicity Among Patients With Hematologic Cancer and Their Caregivers
por: Edward, Jean S., et al.
Publicado: (2023)

Fixed- versus Variable-RBE Computations for Intensity Modulated Proton Therapy
por: Yepes, Pablo, et al.
Publicado: (2018)

Pseudomembranous colitis within radiotherapy field following concurrent chemoradiation therapy: a case report
por: Shen, Bing-Jie, et al.
Publicado: (2013)

The Lived Experiences of Patients with Head and Neck Cancer during Concurrent Chemoradiation Therapy Care Process
por: Kongwattanakul, Sirikorn, et al.
Publicado: (2020)

High-CLDN4 ESCC cells harbor stem-like properties and indicate for poor concurrent chemoradiation therapy response in esophageal squamous cell carcinoma
por: Lin, Cheng-Han, et al.
Publicado: (2019)

2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard
por: Mackler, Emily, et al.
Publicado: (2019)

Proton Beam Therapy for Esophageal Cancer
por: Solidum, Jea Giezl N., et al.
Publicado: (2022)

Trimodal Therapy in Esophageal Squamous Cell Carcinoma: Role of Adjuvant Therapy Following Neoadjuvant Chemoradiation and Surgery
por: Li, Xiaokun, et al.
Publicado: (2022)

Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer
por: Noronha, Vanita, et al.
Publicado: (2016)

The Role of (18) F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy
por: Choi, Jiyoun, et al.
Publicado: (2013)

A prospective comparative study between concurrent chemoradiation with brachytherapy boost with concurrent chemoradiation alone in locally advanced cancer esophagus
por: Tudu, Rajanigandha
Publicado: (2020)

Acute Hematological Toxicity during Cranio-Spinal Proton Therapy in Pediatric Brain Embryonal Tumors
por: Vennarini, Sabina, et al.
Publicado: (2022)

Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer
por: Robinson, Maxwell, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qg65qgpf6ge9gfhktfordd45de